RCOMP is developed by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea.

Last reviewed 2026-04-19 · How we verify

RCOMP

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Phase 2 active Small molecule

At a glance

Generic name	RCOMP
Also known as	Rituximab, Myocet, Cyclophosphamide, Vincristine, Prednisone
Sponsor	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RCOMP CI brief — competitive landscape report
RCOMP updates RSS · CI watch RSS
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea portfolio CI